Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis.
[Charcot and his legacy to medicine].
JC virus Reactivation During Prolonged Natalizumab Monotherapy for Multiple Sclerosis.
Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis.
Remyelination Therapy for Multiple Sclerosis.
Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis.
Synthetic lethality for linking the mycophenolate mofetil mode of action with molecular disease and drug profiles.
Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude.
Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.
Chronic cerebrospinal venous insufficiency and multiple sclerosis: history and background.
HERVs in neuropathogenesis.
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
The grey matter correlates of impaired decision-making in multiple sclerosis.
Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights.
[How to use Japanese guidelines for the treatment of multiple sclerosis].
Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.
Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).
Reply to letter to the editor: "JC viremia and multiple sclerosis" by Focosi et al.
The relation between peptide hormones and sex hormone in patients with multiple sclerosis.
Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study.
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients.
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.
Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis - Yes.
Multiple Sclerosis Increases Fracture Risk: A Meta-Analysis.

Pages